FTSE MIB
34.216,36 -54,76 (-0,16%) Dow Jones
38.460,92 -42,77 (-0,11%) Nasdaq
15.712,75 +16,11 (+0,10%) Nikkei 225
37.628,48 -831,60 (-2,16%) Petrolio
83,02 +0,21 (+0,25%) Bitcoin EUR
59.722,66 -2.567,64 (-4,12%)
Palisade Bio, Inc. (PALI)
Dopo ore:
| Chiusura precedente | 5,92 |
| Aperto | 5,75 |
| Denaro | 5,80 x 100 |
| Lettera | 6,58 x 100 |
| Min-Max giorno | 5,51 - 6,45 |
| Intervallo di 52 settimane | 3,82 - 36,60 |
| Volume | |
| Media Volume | 1.081.812 |
| Capitalizzazione | 5,406M |
| Beta (5 anni mensile) | 1,46 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -27,00 |
| Prossima data utili | 10 mag 2024 - 14 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 33,75 |
GlobeNewswirePalisade Bio to Participate at the Virtual Investor Ask the CEO Conference
Live moderated webcast with J.D. Finley, Chief Executive Officer of Palisade Bio on Wednesday, October 25th at 2:00 PM ET Carlsbad, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that J.D. Finley, Chief Executive Officer of Palisade Bio will participate at the Virtual Investor Ask the CEO Conference on Wednesday, October 25, 2023 at 2:00 PM
- GlobeNewswire
Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules
Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has closed its previously announced registered direct offering with institutional investors for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the registered direct offe
- GlobeNewswire
Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer
Announces Awarding of Inducement Grant to New Chief Medical Officer Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer. Dr. Jones has a proven track record of successfully developing oral biotherapeutics and locally acting immunomodulating t
